Compare Ishares Msci Brazil ETF (EWZ) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ishares Msci Brazil ETF vs Summit Therapeutics Inc — how do they compare? Ishares Msci Brazil ETF trades at $43.54 (market cap $11.30B), while Summit Therapeutics Inc trades at $17.59 (market cap $13.71B). The key difference: Summit Therapeutics Inc is the larger of the two by market cap, and Ishares Msci Brazil ETF is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ishares Msci Brazil ETF for 50 Days and Summit Therapeutics Inc for 16 Days on average.
| EWZ | SMMT | |
|---|---|---|
Market Cap | $11.30B | $13.71B |
Volume | 44,036,597 | 6,173,057 |
Sector | Broad Market / Factor | Health |
52-Week High | $43.00 | $26.38 |
52-Week Low | $28.79 | $12.43 |
Typical Hold Time | 50 Days | 16 Days |
Enterprise Value | — | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWZ, the iShares MSCI Brazil ETF, is trading at $43.54, up 2.76% today, with strong bullish momentum from moving averages but overbought RSI signals. The ETF is positioned as a diversification play against U.S. tech concentration, benefiting from Brazil's commodity exposure and election-driven optimism. Recent unusual options activity and institutional buying reflect heightened investor interest ahead of October's presidential election.
The outlook hinges on Brazil's election outcome and commodity trends, offering asymmetric upside via call spreads. Risks include political volatility, U.S. tariff impacts, and competition from lower-fee Brazil ETFs like FLBR. Wall Street sentiment is cautiously optimistic, with the trade acting as a hedge against AI-driven U.S. market risks.
Summit Therapeutics (SMMT) trades at $17.59, down 2.01% on the day, amid mixed earnings performance but strong analyst support with a consensus price target of $29.33. The stock shows a bullish technical signal from moving averages, with key support at $17 and resistance at $18. Recent news highlights a major $2 billion strategic investment from AstraZeneca and expanded clinical collaborations, boosting investor optimism despite current negative profitability metrics.
The outlook for SMMT is heavily driven by clinical progress and partnerships, offering significant upside if drug trials succeed, but carries high risk due to substantial losses, negative cash flow from operations, and reliance on positive trial outcomes. Investors should weigh the potential rewards against the company's current financial health and execution risks.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
